{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:56:32Z","timestamp":1793382992652,"version":"4.5.0"},"reference-count":38,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2026,4,30]]},"DOI":"10.5582\/bst.2025.01335","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T22:09:22Z","timestamp":1776982162000},"page":"205-216","source":"Crossref","is-referenced-by-count":2,"title":["Comparative safety and efficacy of BIC\/FTC\/TAF versus DTG+3TC in antiretroviral treatment-naive patients with HIV as first-line regimens: A real-world cohort study"],"prefix":"10.5582","volume":"20","author":[{"given":"Liqin","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People&apos;s Hospital, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Jiang","sequence":"additional","affiliation":[{"name":"School of Public Health, Shenzhen University Medical School, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Isnard","sequence":"additional","affiliation":[{"name":"Division of Hematology, Chronic Viral Illness Service, and Research Institute of the McGill University Health Centre, Montreal, QC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Li","sequence":"additional","affiliation":[{"name":"Laboratory of Infectious Diseases, HIV\/AIDS Clinical Treatment Center of Guangxi (Nanning), The Fourth People&apos;s Hospital of Nanning, Nanning, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People&apos;s Hospital, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People&apos;s Hospital, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People&apos;s Hospital, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyun","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People&apos;s Hospital, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Huang","sequence":"additional","affiliation":[{"name":"Laboratory of Infectious Diseases, HIV\/AIDS Clinical Treatment Center of Guangxi (Nanning), The Fourth People&apos;s Hospital of Nanning, Nanning, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwei","family":"Wu","sequence":"additional","affiliation":[{"name":"Laboratory of Infectious Diseases, HIV\/AIDS Clinical Treatment Center of Guangxi (Nanning), The Fourth People&apos;s Hospital of Nanning, Nanning, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinsong","family":"Luo","sequence":"additional","affiliation":[{"name":"School of Public Health, Shenzhen University Medical School, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian","family":"Zhao","sequence":"additional","affiliation":[{"name":"School of Public Health, Shenzhen University Medical School, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenye","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Public Health, Shenzhen University Medical School, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorui","family":"Li","sequence":"additional","affiliation":[{"name":"School of Public Health, Shenzhen University Medical School, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Routy","sequence":"additional","affiliation":[{"name":"Division of Hematology, Chronic Viral Illness Service, and Research Institute of the McGill University Health Centre, Montreal, QC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaye","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Public Health, Shenzhen University Medical School, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"He","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People&apos;s Hospital, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Cen","sequence":"additional","affiliation":[{"name":"Laboratory of Infectious Diseases, HIV\/AIDS Clinical Treatment Center of Guangxi (Nanning), The Fourth People&apos;s Hospital of Nanning, Nanning, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhou","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People&apos;s Hospital, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","unstructured":"1. UNAIDS. Global HIV &amp; AIDS statistics\u2014Fact sheet <i>https:\/\/www.unaids.org\/en\/resources\/fact-sheet<\/i> (accessed April 1, 2026)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Gandhi RT, Landovitz RJ, Sax PE, <i>et al<\/i>. Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2025; 333:609-628.","DOI":"10.1001\/jama.2024.24543"},{"key":"3","unstructured":"3. World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach.<i>https:\/\/www.who.int\/publications\/i\/item\/9789240031593<\/i> (accessed April 1, 2026)."},{"key":"4","unstructured":"4. Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. <i>https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new.<\/i> (accessed April 1, 2026)."},{"key":"5","unstructured":"5. EACS Guidelines version 13.0, October 2025. <i>https:\/\/www.eatg.org\/hiv-news\/eacs-guidelines-2025-version-13-0\/<\/i> (accessed October 18, 2025)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Cahn P, Madero JS, Arribas JR, <i>et al<\/i>. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate\/emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019; 393:143-155.","DOI":"10.1016\/S0140-6736(18)32462-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Gallant J, Lazzarin A, Mills A, <i>et al<\/i>. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017; 390:2063-2072.","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Osiyemi O, De Wit S, Ajana F, <i>et al<\/i>. Efficacy and Safety of Switching to Dolutegravir\/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial. Clin Infect Dis.2022; 75:975-986.","DOI":"10.1093\/cid\/ciac036"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Zhao F, Lu H. Renal safety of tenofovir alafenamide-based antiretroviral therapy in people with HIV: a mini-review. BioSci Trends. 2024; 18:141-152.","DOI":"10.5582\/bst.2024.01062"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sax PE, Erlandson KM, Lake JE, <i>et al<\/i>. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis. 2020; 71:1379-1389.","DOI":"10.1093\/cid\/ciz999"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hill A, Hughes SL, Gotham D, Pozniak AL. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? J Virus Erad. 2018; 4:72-79.","DOI":"10.1016\/S2055-6640(20)30248-X"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lake JE, Currier JS. Metabolic disease in HIV infection. Lancet Infect Dis. 2013; 13:964-975.","DOI":"10.1016\/S1473-3099(13)70271-8"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Acquired Immunodeficiency Syndrome Professional Group, Society of Infectious Diseases, Chinese Medical Association; Chinese Center for Disease Control and Prevention. Chinese guidelines for the diagnosis and treatment of human immunodeficiency virus infection\/acquired immunodeficiency syndrome (2024 edition). Chin Med J (Engl). 2024; 137:2654-2680.","DOI":"10.1097\/CM9.0000000000003383"},{"key":"14","unstructured":"14. Joint Committee for the Revision of Chinese Guidelines for the Management of Dyslipidemia. Chinese guidelines for the management of dyslipidemia in adults (2023 edition). Beijing: People&apos;s Medical Publishing House; 2023."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Chalasani N, Younossi Z, Lavine JE, <i>et al<\/i>. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67:328-357.","DOI":"10.1002\/hep.29367"},{"key":"16","unstructured":"16. Chinese Diabetes Society. Guidelines for the prevention and treatment of type 2 diabetes in China (2024 edition). Chin J Diabetes Mellitus. 2024; 16:1-58."},{"key":"17","unstructured":"17. National Kidney Foundation. K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39: S1-266."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Wohl DA, Yazdanpanah Y, Baumgarten A, <i>et al<\/i>. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019; 6:e355-e363.","DOI":"10.1016\/S2352-3018(19)30077-3"},{"key":"19","unstructured":"19. P\u00e9rez-Valero I, Corona Mata D, Camacho Espejo A, <i>et al<\/i>. Cohorte de la Red Espa\u00f1ola de Investigaci\u00f3n en SIDA (CoRIS) Cohort. Real-world Effectiveness and Safety of Bictegravir\/Emtricitabine\/Tenofovir Alafenamide in Comparison With Other Regimens in People With HIV Starting Therapy With AIDS-Defining Conditions: Results From the CoRIS Cohort-The ACTUAS II Study. Clin Infect Dis. 2025;81: e93-e101."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Fraysse J, Priest J, Turner M, Hill S, Jones B, Verdier G, Letang E. Real-World Effectiveness and Tolerability of Dolutegravir and Lamivudine 2-Drug Regimen in People Living with HIV: Systematic Literature Review and Meta-Analysis. Infect Dis Ther. 2025; 14:357-383.","DOI":"10.1007\/s40121-024-01103-0"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Tao M, Xia M, Yu T, Li B, Peng J, Cai S, Xu X. Longitudinal analysis of metabolic changes in people with HIV on integrase inhibitor-based versus efavirenz-based therapy: a prospective real-world cohort study in China. BMC Infect Dis. 2026; 26:302.","DOI":"10.1186\/s12879-026-12553-x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Llibre JM, Brites C, Cheng CY, <i>et al<\/i>. Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir\/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial. Clin Infect Dis. 2023; 76:720-729.","DOI":"10.1093\/cid\/ciac130"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Gan L, Xie X, Fu Y, Yang X, Ma S, Kong L, Song C, Song Y, Ren T, Long H. Bictegravir\/Emtricitabine\/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study. Infect Dis Ther. 2023; 12:2581-2593.","DOI":"10.1007\/s40121-023-00879-x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Shi J, Zhang W, Han J, Zhang Z, Yan D, Zheng R, Li F, Wang Y. Metabolic Health Consequences of Switching to the Bictegravir\/Emtricitabine\/Tenofovir Alafenamide and Dolutegravir Plus Lamivudine Regimens in Virologically Suppressed People Living with HIV Aged &gt; 40 Years: A Retrospective Real-World Study. Infect Drug Resist. 2025; 18:2703-2716.","DOI":"10.2147\/IDR.S516775"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Sokhela S, Venter WDF, Bosch B, <i>et al<\/i>. Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens. Open Forum Infect Dis. 2024;11: ofae007.","DOI":"10.1093\/ofid\/ofae007"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Mallon PW, Brunet L, Hsu RK, Fusco JS, Mounzer KC, Prajapati G, Beyer AP, Wohlfeiler MB, Fusco GP. Weight gain before and after switch from TDF to TAF in a U.S. cohort study. J Int AIDS Soc. 2021; 24:e25702.","DOI":"10.1002\/jia2.25702"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Wohl DA, Koethe JR, Sax PE, McComsey GA, Kuritzkes DR, Moyle G, Kaplan L, van Wyk J, Campo RE, Cohen C. Antiretrovirals and Weight Change: Weighing the Evidence. Clin Infect Dis. 2024; 79:999-1005.","DOI":"10.1093\/cid\/ciae191"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Palella FJ, Hou Q, Li J, Mahnken J, Carlson KJ, Durham M, Ward D, Fuhrer J, Tedaldi E, Novak R, Buchacz K. Weight Gain and Metabolic Effects in Persons With HIV Who Switch to ART Regimens Containing Integrase Inhibitors or Tenofovir Alafenamide. J Acquir Immune Defic Syndr. 2023; 92:67-75.","DOI":"10.1097\/QAI.0000000000003101"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Yang J, Wang L, Zhang X, <i>et al<\/i>. Safety and efficacy of lamivudine\/dolutegravir <i>vs.<\/i> bictegravir\/emtricitabine\/tenofovir alafenamide in antiretroviral-naive adults with HIV-1 infection in Shanghai, China: a single-centre retrospective study. J Med Microbiol. 2025; 74:001949.","DOI":"10.1099\/jmm.0.001949"},{"key":"30","unstructured":"30. Damas J, Munting A, Fellay J, <i>et al<\/i>. Swiss HIV Cohort Study (SHCS): Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide in People With HIV. Clin Infect Dis. 2024; 79:990-998."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Li X, Sun L, He Y, Zhao F, Luo Y, Liu C, Hu Y, Jiang Y, Lu H, Liu J. HDL-C as a novel predictor of immune reconstitution in people living with HIV: insights from a baseline-to-dynamic change cohort study in China, 2005-2022. Front Immunol. 2025; 16:1520615.","DOI":"10.3389\/fimmu.2025.1520615"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Luo Y, Sun L, He Y, Zhao F, Shan D, Bu F, Ge L, Li X, Hu Y, Xiao X, Lu H, Liu J. The triglyceride-glucose index trajectories are associated with cardiovascular diseases in people living with HIV: evidence from a prospective cohort study in China, 2005-2022. BMC Public Health. 2025; 25:465.","DOI":"10.1186\/s12889-025-21744-1"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Sun L, Luo Y, Jia X, Wang H, Zhao F, Zhang L, Ju B, Wang H, Shan D, He Y, Lu H, Liu J. Association between the triglyceride to high-density lipoprotein cholesterol ratio and cardiovascular diseases in people living with human immunodeficiency virus: Evidence from a retrospectively cohort study 2005-2022. Chin Med J (Engl). 2024; 137:2712-2719.","DOI":"10.1097\/CM9.0000000000003326"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Eckard AR, McComsey GA. Weight gain and integrase inhibitors. Curr Opin Infect Dis. 2020; 33:10-19.","DOI":"10.1097\/QCO.0000000000000616"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Kerchberger AM, Sheth AN, Angert CD, <i>et al<\/i>. Weight Gain Associated With Integrase Stand Transfer Inhibitor Use in Women. Clin Infect Dis. 2020; 71:593-600.","DOI":"10.1093\/cid\/ciz853"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Cahn P, Pozniak AL, Mingrone H, <i>et al<\/i>. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013; 382:700-708.","DOI":"10.1016\/S0140-6736(13)61221-0"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Milburn J, Jones R, Levy JB. Renal effects of novel antiretroviral drugs. Nephrol Dial Transplant. 2017; 32:434-439.","DOI":"10.1093\/ndt\/gfw064"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Lee DH, Malat GE, Bias TE, Harhay MN, Ranganna K, Doyle AM. Serum creatinine elevation after switch to dolutegravir in a human immunodeficiency virus-positive kidney transplant recipient. Transpl Infect Dis. 2016; 18:625-627.","DOI":"10.1111\/tid.12545"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/20\/2\/20_2025.01335\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T03:27:16Z","timestamp":1779506836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/20\/2\/20_2025.01335\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2025.01335","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"article-number":"2025.01335"}}